Stock Scorer

Cardiol Therapeutics Inc. (CRDL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in CAD. Every figure as a table ›

Revenue Annual

0 700K 1.4M 2.1M FY21: 106K FY22: 1.2M FY23: 2M FY24: 1.2M FY25: 726.4K FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-45M -30M -15M 0 15M 30M 45M FY21: -38.7M FY22: -41.3M FY23: -29.8M FY24: -40.3M FY25: -34.3M FY21 FY22 FY23 FY24 FY25

Net Income Annual

-45M -30M -15M 0 15M 30M 45M FY21: -31.6M FY22: -30.9M FY23: -28.1M FY24: -36.7M FY25: -33.8M FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-30M -20M -10M 0 10M 20M 30M FY21: -23.5M FY22: -27.2M FY23: -25.2M FY24: -25.1M FY25: -23.9M FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-30M -20M -10M 0 10M 20M 30M FY21: -23.6M FY22: -27.3M FY23: -25.2M FY24: -25.1M FY25: -23.9M FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 30M 60M 90M FY21: 43.2M FY22: 62.5M FY23: 64.5M FY24: 71.6M FY25: 87M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS Annual

-0.75 -0.50 -0.25 0.00 0.25 0.50 0.75 FY21: -0.73 FY22: -0.49 FY23: -0.44 FY24: -0.51 FY25: -0.39 FY21 FY22 FY23 FY24 FY25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for CRDL: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.